Blue Trust Inc. Reduces Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Blue Trust Inc. cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 40.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,026 shares of the medical equipment provider’s stock after selling 693 shares during the period. Blue Trust Inc.’s holdings in Zimmer Biomet were worth $108,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. International Assets Investment Management LLC grew its position in Zimmer Biomet by 19,988.0% during the third quarter. International Assets Investment Management LLC now owns 107,471 shares of the medical equipment provider’s stock valued at $11,601,000 after acquiring an additional 106,936 shares during the period. Assenagon Asset Management S.A. raised its position in Zimmer Biomet by 15.9% in the third quarter. Assenagon Asset Management S.A. now owns 28,145 shares of the medical equipment provider’s stock valued at $3,038,000 after purchasing an additional 3,859 shares during the period. Tectonic Advisors LLC lifted its stake in shares of Zimmer Biomet by 20.8% during the third quarter. Tectonic Advisors LLC now owns 3,647 shares of the medical equipment provider’s stock worth $394,000 after purchasing an additional 629 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Zimmer Biomet by 26.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,511 shares of the medical equipment provider’s stock worth $1,895,000 after buying an additional 3,633 shares during the period. Finally, Forsta AP Fonden grew its stake in shares of Zimmer Biomet by 14.5% in the third quarter. Forsta AP Fonden now owns 97,400 shares of the medical equipment provider’s stock valued at $10,514,000 after buying an additional 12,300 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $104.89 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $20.88 billion, a PE ratio of 23.57, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The firm has a 50-day moving average price of $105.86 and a 200 day moving average price of $107.45.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the business earned $2.20 earnings per share. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were paid a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 21.57%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Truist Financial reaffirmed a “hold” rating and set a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Barclays reduced their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Finally, Royal Bank of Canada cut their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.